Tag: tavapadon
-
AbbVie’s Juvmo Wins FDA Approval for Parkinson’s Disease
The FDA approved AbbVie’s Juvmo (tavapadon), a once-daily oral D1/D5 dopamine receptor partial agonist, for adults with Parkinson’s disease. Phase 3 TEMPO data support its efficacy, while pricing, coverage and real-world tolerability remain key commercial questions.
-
AbbVie Juvmo Mechanism: D1/D5 Partial Agonism in Parkinson’s Disease
Juvmo partially activates D1/D5 receptors and re-engages Gαolf/Gs–AC5–cAMP–PKA–DARPP-32 signaling in Parkinson’s disease. The therapy improves symptomatic motor signaling without restoring dopamine production or lost dopaminergic neurons.